Compensatory Mechanisms in Experimental and Human Parkinsonism: Potential for New Therapies Chapter 37
Compensatory Mechanisms in Experimental and Human Parkinsonism: Potential for New Therapies Chapter 37
复制标题
实验和人类帕金森病的补偿机制:新疗法的潜力第 37 章
DOI:
--
复制
发表时间:
2010
期刊:
影响因子:
--
通讯作者:
J. Obeso
中科院分区:
文献类型:
--
作者:
E. Bézard;G. Porras;J. Blesa;J. Obeso
Parkinson’s disease (PD) is a widespread neurodegen-erative disorder, the major pathologic feature of which is the profound loss of pigmented dopamine (DA) neu-rons, mainly in the pars compacta of the substantia nigra (SNc) (Hassler, 1938; Ehringer and Hornykiewicz, 1960) (see also Chapter 34). The cardinal features of PD, that is, tremor, rigidity and bradykinesia (Singh et al., 2007), typically arise when DA neuronal death reaches a critical threshold: 70–80% of striatal nerve terminals and 50–60% of SNc perikarya (Bernheimer et al., 1973). This dissocia-tion between the onset of parkinsonian motor features and the presence of large DA depletions is understood as a con-sequence of compensatory mechanisms (Zigmond et al., 1990; Bezard and Gross, 1998; Bezard et al., 2003). Thus, compensatory mechanisms can delay the clinical onset of PD and could also play a role in the progression of motor deficits. Indeed, it is quite possible that compensatory
DOI:
10.1073/pnas.0409766102
发表时间:
2005-03-01
影响因子:
11.1
作者:
Seeman, P;Weinshenker, D;Tallerico, T
通讯作者:
Tallerico, T
影响因子:
14.5
作者:
Huang, Chaorui;Tang, Chengke;Eidelberg, David
通讯作者:
Eidelberg, David
DOI:
--
发表时间:
1990
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
Snyder,GL;KellerJr,RW;Zigmond,MJ
通讯作者:
Zigmond,MJ